drugset / Trial / NCT06518668
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
Phase 1
Enrolling by invitation
6 enrolled
Hospital for Special Surgery, New York
Nkarta, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
Primary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD). Secondary objectives: * Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN) * Characterize pharmacokinetics (PK) of NKX019 * Characterize immunogenicity of NKX019
Timeline
- Start
- 2024-07-01
- Primary completion
- 2026-12
- Completion
- 2040-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NKX019 | Cell therapy | 1e+09 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | Intravenous |